No Results Found
Try adjusting your search to find what you’re looking for.
10/03/2023
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
Iambic’s unique AI-Driven drug-discovery platform identifies potential first-in-class and best-in-class development candidates years faster than industry norms. Funding will support continued AI platform innovations and advancement of multiple candidates into clinical development, Including IAM-H1, a selective brain-penetrant HER2 Inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor.
Read More
9/18/2023
Broken String Biosciences Closes $15M Series A Funding Round
Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners...
Read More
8/18/2023
Lightcast Discovery secures $49 million in Series B financing to commercialize its single-cell platform for functional analysis
Lightcast Discovery Ltd. (“Lightcast” or the “Company”), a life science tools company developing a novel single-cell functional analysis platform, today announced the completion of a £38M (c. $49 million) Series B funding round, led by M Ventures.
Read More
6/20/2023
Attovia Therapeutics Launches With $60 Million Series A Financing To Unlock Potential Of Novel Biparatopic Nanobody Platform
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer.
Read More
